60 DEGREES PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.0M | $607,574 | $253,573 | $223,208 | — |
| Cost of revenue | $781,695 | $384,765 | $474,550 | $432,370 | — |
| Gross profit | $223,776 | $222,809 | -$220,977 | -$209,162 | — |
| Research and development | $2.1M | $5.0M | $691,770 | $525,563 | — |
| Operating expenses | $8.4M | $10.0M | $4.9M | $1.8M | — |
| Operating income | -$7.8M | -$9.7M | -$5.2M | -$1.8M | — |
| Interest expense | $7,805 | $7,912 | $2.3M | $4.0M | — |
| Pretax income | -$7.4M | -$8.0M | -$3.8M | -$6.2M | — |
| Income tax expense | $0 | $0 | $250 | $500 | — |
| Net income | -$7.4M | -$7.9M | -$3.8M | -$6.2M | — |
| Balance Sheet | |||||
| Cash and equivalents | $1.5M | $1.7M | $2.1M | — | — |
| Current assets | $4.9M | $5.4M | $7.2M | $1.1M | — |
| Total assets | $5.4M | $5.8M | $7.8M | $1.3M | — |
| Current liabilities | $1.8M | $1.7M | $2.8M | $23.9M | — |
| Total liabilities | $2.0M | $1.8M | $3.0M | $25.4M | — |
| Total debt | — | — | — | $3.0M | — |
| Stockholders' equity | $3.5M | $4.0M | $4.9M | -$23.6M | -$18.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.8M | -$5.6M | -$4.5M | -$1.0M | — |
| Depreciation and amortization | $43,324 | $11,726 | $21,162 | $27,648 | — |
| Stock-based compensation | $456,344 | $3.6M | $212,605 | $0 | — |
| Capital expenditure | $139,881 | $103,773 | $57,623 | — | — |
| Free cash flow | -$7.0M | -$5.8M | -$4.6M | — | — |
Shares outstanding 2.7M · Free float 59.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.